Department of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Cell Death Dis. 2023 Aug 17;14(8):529. doi: 10.1038/s41419-023-06048-9.
Osteosarcoma is a highly aggressive malignant tumor that is common in the pediatric population and has a high rate of disability and mortality. Recent studies have suggested that the tripartite motif-containing family genes (TRIMs) play critical roles in oncogenesis in several cancers. TRIM26, one of the TRIMs family genes, was more frequently reported to exert a tumor-suppressive role, while its detailed functional roles in the osteosarcoma progression were still unknown and require further investigation. Herein, we found that TRIM26 was markedly downregulated in osteosarcoma tissues and cells. Survival analysis revealed that higher expression of TRIM26 was associated with better prognosis and its expression was an independent protective factor in osteosarcoma. Functional analysis demonstrated that overexpression of TRIM26 inhibited osteosarcoma cell proliferation and invasion via inhibiting the EMT process and MEK/ERK signaling. In contrast, the silence of TRIM26 caused the opposite effect. RACK1, a member of the Trp-Asp repeat protein family, was identified as a novel target of TRIM26. TRIM26 could interact with RACK1 and accelerate the degradation of RACK1, thus inactivation of MEK/ERK signaling. Overexpression of RACK1 could attenuate the inhibitory effect of TRIM26 overexpression on p-MEK1/2 and p-ERK1/2, and silence of RACK1 could partly impair the effect of TRIM26 knockdown-induced upregulation of p-MEK1/2 and p-ERK1/2. Further, a series of gain- and loss-of-function experiments showed that decreased malignant behaviors including cell proliferation and invasion in TRIM26-upregulated cells were reversed when RACK1 was overexpressed, whereas RACK1 knockdown diminished the increased malignant phenotypes in TRIM26-silenced osteosarcoma cells. In conclusion, our study indicated that TRIM26 inhibited osteosarcoma progression via promoting proteasomal degradation of RACK1, thereby resulting in inactivation of MEK/ERK signaling, and impeding the EMT process.
骨肉瘤是一种高度侵袭性的恶性肿瘤,常见于儿童人群,致残率和死亡率较高。最近的研究表明,三结构域包含家族基因(TRIMs)在几种癌症的肿瘤发生中发挥着关键作用。TRIMs 家族基因中的 TRIM26 更常被报道发挥肿瘤抑制作用,但其在骨肉瘤进展中的详细功能作用尚不清楚,需要进一步研究。在此,我们发现 TRIM26 在骨肉瘤组织和细胞中明显下调。生存分析表明,TRIM26 表达较高与预后较好相关,其表达是骨肉瘤的独立保护因素。功能分析表明,过表达 TRIM26 通过抑制 EMT 过程和 MEK/ERK 信号通路抑制骨肉瘤细胞增殖和侵袭。相反,沉默 TRIM26 则产生相反的效果。RACK1,一种色氨酸-天冬氨酸重复蛋白家族的成员,被鉴定为 TRIM26 的一个新靶标。TRIM26 可以与 RACK1 相互作用并加速 RACK1 的降解,从而使 MEK/ERK 信号失活。过表达 RACK1 可以减弱 TRIM26 过表达对 p-MEK1/2 和 p-ERK1/2 的抑制作用,而沉默 RACK1 可以部分削弱 TRIM26 敲低诱导的 p-MEK1/2 和 p-ERK1/2 上调的作用。此外,一系列的功能获得和缺失实验表明,在过表达 TRIM26 的细胞中,细胞增殖和侵袭等恶性行为的降低可以被 RACK1 过表达逆转,而在沉默 TRIM26 的骨肉瘤细胞中,RACK1 敲低则减弱了增加的恶性表型。总之,我们的研究表明,TRIM26 通过促进 RACK1 的蛋白酶体降解来抑制骨肉瘤的进展,从而导致 MEK/ERK 信号失活,并阻碍 EMT 过程。